Skip to main content

Instead of Chasing Every New Vaccine "Breakthrough," Trade the Whole Sector

Not every biotech company is doing well in the search for an effective COVID-19 vaccine or treatment. And the latest firm to struggle is Eli Lilly, whose antibody clinical trial was paused due to failure to show any real results. So today, Andrew's going to show you a much more profitable move to make instead of chasing every vaccine "breakthrough" news... Read more... Tags: biotech stocks To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2020 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post Instead of Chasing Every New Vaccine "Breakthrough," Trade the Whole Sector appeared first on Money Morning - We Make Investing Profitable .
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.